ArticleJournal for immunotherapy of cancer2019
Two roads for oncolytic immunotherapy development.
Article in Journal for immunotherapy of cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Vaccinia virus armed with IL-21 can cure murine colorectal cancer liver metastases via intravenous administration.Journal for immunotherapy of cancer · 2026Article
- Oncolytic viruses: advanced strategies in cancer therapy.Signal transduction and targeted therapy · 2026Review
- Advances in IL-2 Family Cytokine-Based Cancer Therapies: Overcoming Challenges Through Molecular Engineering and Delivery Strategies.Immune network · 2026Review
- Side-stepping the guardian of the genome: current cancer therapeutics targeting mutant p53.Frontiers in pharmacology · 2025Review
- Intratumoral Injection of Immunotherapeutics: State of the Art and Future Directions.Radiology · 2024Review
- Microbiome and cancer: from mechanistic implications in disease progression and treatment to development of novel antitumoral strategies.Frontiers in immunology · 2024Review
- Biosafety and biohazard considerations of HSV-1-based oncolytic viral immunotherapy.Frontiers in molecular biosciences · 2023Review
- Development and application of oncolytic viruses as the nemesis of tumor cells.Frontiers in microbiology · 2023Review
- DNA Origami Disguises Herpes Simplex Virus 1 Particles and Controls Their Virulence.Molecules (Basel, Switzerland) · 2022Article
- Preinduced reovirus-specific T-cell immunity enhances the anticancer efficacy of reovirus therapy.Journal for immunotherapy of cancer · 2022Article
- The Current State of Treatment and Future Directions in Cutaneous Malignant Melanoma.Biomedicines · 2022Review
- The Landscape of Nanovectors for Modulation in Cancer Immunotherapy.Pharmaceutics · 2022Review
- Review
- Polymer Coated Oncolytic Adenovirus to Selectively Target Hepatocellular Carcinoma Cells.Pharmaceutics · 2021Article
- Human immunology and immunotherapy: main achievements and challenges.Cellular & molecular immunology · 2021Review
- Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany.Journal for immunotherapy of cancer · 2021Article
- Mechanistic Modeling of a Novel Oncolytic Virus, V937, to Describe Viral Kinetic and Dynamic Processes Following Intratumoral and Intravenous Administration.Frontiers in pharmacology · 2021Article
- Clinical landscape of oncolytic virus research in 2020.Journal for immunotherapy of cancer · 2020Review
- Myxoma Virus-Loaded Mesenchymal Stem Cells in Experimental Oncolytic Therapy of Murine Pulmonary Melanoma.Molecular therapy oncolytics · 2020Article
- Advances in engineering local drug delivery systems for cancer immunotherapy.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2020Review
Corrections and comments
- Comment on
- Erratum issuedCorrection:2021
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oncolytic viruses are an emerging class of immunotherapy agents for cancer treatment. In this issue of JITC, Machiels et al. reports early phase data from an oncolytic adenovirus given by intravenous (IV) administration. While this may allow easy access to metastatic lesions, there is limited data supporting the therapeutic effectiveness of this approach. Further studies should include assessment of viral replication in tumor tissue and consider comparative trials using IV and intratumoral delivery to fully optimize oncolytic immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.